June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Two Year Visual Acuity Outcomes in Clinical Practice of Diabetic Macular Edema Treated with Anti-VEGF Therapy in an US Integrated Healthcare System
Author Affiliations & Notes
  • Donald S Fong
    Ophthalmology, Kaiser Permanente Southern California, Baldwin Park, CA
  • Tiffany Luong
    Research and Evaluation, Kaiser Permenante, Pasadena, CA
  • Richard Contreras
    Research and Evaluation, Kaiser Permenante, Pasadena, CA
  • Jennifer Jimenez
    Research and Evaluation, Kaiser Permenante, Pasadena, CA
  • Peter Custis
    Ophthalmology, Kaiser Permanente, San Diego, CA
  • Vaishali D Patel
    Allergan, Irvine, CA
  • Joanna Campbell
    Allergan, Irvine, CA
  • Footnotes
    Commercial Relationships Donald Fong, Allergan (R); Tiffany Luong, None; Richard Contreras, None; Jennifer Jimenez, None; Peter Custis, None; Vaishali Patel, Allergan (E); Joanna Campbell, Allergan (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1418. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Donald S Fong, Tiffany Luong, Richard Contreras, Jennifer Jimenez, Peter Custis, Vaishali D Patel, Joanna Campbell; Two Year Visual Acuity Outcomes in Clinical Practice of Diabetic Macular Edema Treated with Anti-VEGF Therapy in an US Integrated Healthcare System. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1418. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Determine the long-term real-world effectiveness of intravitreal anti-VEGF therapy in patients with newly diagnosed diabetic macular edema (DME) treated in clinical practice.

Methods: Patients with DME were identified from Kaiser Permanente’s 350,000 patients with diabetes mellitus treated between 2008 and 2013. Patients were eligible if they had a new diagnosis of DME and received an intravitreal bevacizumab injection within 12 months of initial diagnosis. Patients with AMD or vein occlusion were excluded. Visual acuity (VA), number of intravitreal injections and patient characteristics were abstracted from the electronic record. The main outcome measure was change in VA at 3, 6, 9, 12, and 24 months of follow-up. Snellen visual acuities were converted to ETDRS letter equivalents using a published algorithm. Missing VA data was imputed using the last observation carried forward (LOCF) method.

Results: A total of 366 patients met all inclusion criteria and had 2 years of follow-up after their first bevacizumab injection. At baseline, 20.8% of patients had VA better than or equal to 20/40 and 12.3% had a VA worse than 20/200. In this cohort, patients had a mean of 3.1 injections (range, 1-17) during the 2-year follow-up. Mean VA improvement was 4.1 letters at 12 months, and 4.9 letters at 24 months. Only 29.8% of patients (ETDRS score of ≤ 70 at baseline, N = 325) demonstrated > 3 lines of improvement from baseline in their vision; while 12.3% of all patients reported > 3 lines of vision loss from baseline.

Conclusions: The current study is the largest long-term US clinical practice based study of anti-VEGF use for diabetic macular edema. The frequency of injection was low, with less average VA improvement than in anti-VEGF trials. Significant visual acuity improvement was achieved in about 30% of patients. There is opportunity for greater vision improvement with more frequent injections or treatments with longer duration of action. Future studies will look at more recent data using other agents.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.